BMY News and Press, Bristol-Myers Squibb Company From 04/07/24

2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...

2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...

2024-04-06 15:21:29 ET More on Bristol-Myers Squibb Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis) Bristol Myers Squibb: The Comeback Is Unfolding Bristol-Myers Squibb Is Not A Buy For Me Bristol Myers, 2seventy bio's Abecma ap...

KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients (65%) experienced reductions in weight over the course of the trial, with a mean weight decrea...

Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of participants achieved > 30% improvement in symptoms from baseline, as measured by the Positive and Negative Syndrome ...

2024-04-06 09:30:00 ET Summary This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks ...

2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...

2024-04-05 09:33:47 ET Bristol Myers Squibb ( NYSE: BMY ) said on Friday that the company and 2seventy bio ( NASDAQ: TSVT ) received U.S. FDA approval for Abecma in the treatment of adult patients with relapsed or refractory multiple myeloma.... Rea...

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more pati...

2024-04-04 11:12:55 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli...